MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-31-2023
Ayala Pharmaceuticals DPO Ratio 2011-2026 | AYLA
Annual DPO Ratio Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.21 K | 361 | 367 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.21 K | 361 | 980 |
Quarterly DPO Ratio Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.8 K | 6.99 K | 716 | - | 418 | 350 | 315 | - | 517 | 325 | 303 | - | 550 | 1.67 K | 503 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.99 K | 303 | 1.29 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
58.1 | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
28.6 K | $ 20.25 | -0.54 % | $ 2.83 B |  France |
 |
Aytu BioScience
AYTU
|
186 | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
105 | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Evogene Ltd.
EVGN
|
62.6 | $ 0.8 | 2.49 % | $ 27.9 M |  Israel |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
894 | $ 6.2 | -3.43 % | $ 177 M | USA |
 |
Amicus Therapeutics
FOLD
|
104 | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Gilead Sciences
GILD
|
45.3 | $ 138.37 | -1.26 % | $ 172 B | USA |